News & Investors

Want to stay updated? Subscribe to our newsletters. For free.

Have questions? Our live support would be happy to help you.

12.12.2013 | 131212_Epigenomics_press_release_MACSF

Berlin, Germany, and U.S.A. – Epigenomics AG (Frankfurt Prime Standard: ECX, OTC: EPGNY), the German-American cancer molecular diagnostics company, today announced that MACSF (Mutuelle d’Assurance du Corps de Santé Français), the leading French supplementary insurance provider for the medical community, will provide the blood-based Septin9 test for the early detection of colorectal cancer (CRC) as part of their additional health insurance program. MACSF will reimburse EUR 50 on what its policy holders pay for undergoing Septin9 testing.

MACSF offers about 800.000 policy holders from the medical community and their families, such as doctors from the private and public sector, other medical or paramedical workers including medical students an additional health insurance, called “Mutuelle”. After Swiss Life announced to provide Septin9 as part of its preventive health program in July 2012, MACSF is the second healthcare provider in France and the first “Mutuelle” to reimburse blood-based colorectal cancer screening.

Dr. Thomas Taapken, CEO/CFO of Epigenomics, commented: “We are extremely pleased to experience this growing support by French insurance providers. The fact that also MACSF now offers blood-based Septin9 tests to its customers shows the importance of an alternative convenient and non-invasive screening method. And, as their policy holders originate primarily from the medical community, we also hope to raise awareness and convince doctors of our Septin9-based test Epi proColon®, so that they increasingly recommend it to their patients”.

– Ends –

About Epigenomics

Epigenomics (www.epigenomics.com) is a molecular diagnostics company developing and commercializing a pipeline of proprietary products for cancer. The Company’s products enable doctors to diagnose cancer earlier and more accurately, leading to improved outcomes for patients. Epigenomics’ lead product, Epi proColon®, is a blood-based test for the early detection of colorectal cancer, which is currently marketed in Europe and is in development for the U.S.A and China. The Company’s technology and products have been validated through multiple partnerships with leading global diagnostic companies and testing laboratories. Epigenomics is an international company with operations in Europe and the U.S.A.

About MACSF

MACSF Group (Mutuelle d’Assurance du Corps de Santé Français) is for over 75 years the leading insurance provider for healthcare professionals in France. Its mission is to provide supplementary insurance services for private or work-related risks for its members working in the private or public healthcare space.

Contact Epigenomics AG

Antje Zeise, Manager IR | PR
Epigenomics AG
Kleine Praesidentenstrasse 1
10178 Berlin
Tel +49 (0) 30 24345 386
ir@epigenomics.com
www.epigenomics.com

For US press inquiries:

Epigenomics, Inc.
9700 Great Seneca Highway Rockville
Maryland 20850
pr@epigenomics.com

Epigenomics legal disclaimer

This communication expressly or implicitly contains certain forward-looking statements concerning Epigenomics AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of Epigenomics AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Epigenomics AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.
The information contained in this communication does not constitute nor imply an offer to sell or transfer any product, and no product based on this technology is currently available for sale by Epigenomics in the United States or Canada. The analytical and clinical performance characteristics of any Epigenomics product based on this technology which may be sold at some future time in the U.S. have not been established.